Hayley Virgil is a senior editor with CancerNetwork. When she isn't traveling to conferences and championing health equity in the oncology space, she can be found hiking, foraging wild plants, gardening, sewing ballgowns, practicing embroidery, or playing video games.
Investigators Provide Long-Term Follow-Up for 2 Phase 3 Trials of PCV Chemotherapy/RT for Anaplastic Oligodendroglial TumorsJune 30th 2022
According to long-term data, first-line treatment with procarbazine, lomustine, and vincristine chemotherapy plus radiotherapy offered prolonged disease control and survival benefit in anaplastic oligodendroglial tumors.
Punctual, Kinetic MRD Analysis May Be MCL Natural History, Progression, and Outcomes IndicatorJune 29th 2022
Punctual and kinetic minimal residual disease analysis could be a robust predictor of mantle cell lymphoma’s natural history and could represent an adaptable model for continuous patient risk assessment.
From Increased Risks to Care Barriers: Experts Highlight Unique Challenges of LGBTQ+ Cancer CommunityJune 28th 2022
Key leaders in the oncology space discuss unique cancer risk factors, barriers to care, and ways in which institutions and organizations are creating more welcoming environments for individuals within the LGBTQ+ community.
Primary Transoral Surgery Yields Good Swallowing Outcomes Despite Increased Risk of Death in HPV-related OPSCCJune 28th 2022
Despite an increased risk of grade 5 toxicities, patients with human papillomavirus–related oropharyngeal squamous cell carcinoma who received primary transoral surgery and neck dissection vs radiotherapy experienced good swallowing outcomes at 1 year.
Adjuvant Abemaciclib Plus Endocrine Therapy Yields Improved Outcomes in HR+ ERBB2– High-Risk Early Breast CancerJune 27th 2022
Patients with hormone receptor–positive, ERBB2-negative high-risk early breast cancer who received neoadjuvant chemotherapy and adjuvant abemaciclib plus endocrine therapy experienced invasive disease-free survival and distant relapse-free survival benefit vs those with adjuvant endocrine therapy alone.
Cohort Study Identifies Factors Independently Associated With Breast Cancer–Related Lymphedema Risk Post-ALNDJune 25th 2022
After identifying several factors independently associated with the risk of breast cancer–related lymphedema following axillary lymph node dissection, investigators recommend further studies to examine biologic mechanisms behind racial and ethnic disparities within this space.
Venetoclax Plus Obinutuzumab Yield PFS Improvement in Untreated CLL, With or Without IbrutinibJune 16th 2022
Patients with treatment-naïve chronic lymphocytic leukemia who were treated with venetoclax and obinutuzumab with or without ibrutinib experienced a progression-free survival benefit compared with standard chemoimmunotherapy.
No Difference in Survival Observed in Uterine Carcinosarcoma Following SLN Biopsy vs Systemic LNDJune 15th 2022
Patients with uterine carcinosarcoma who underwent sentinel lymph node biopsy or systemic lymph node dissection did not experience a difference in progression-free survival or overall survival.
Lifting the Stigma: The Importance of HPV Vaccination Education in Head and Neck CancerJune 14th 2022
Tom Thomas, MD, highlights how the stigma surrounding human papillomavirus–associated head and neck cancer is being unraveled through education and the importance of vaccination as a prevention strategy.
Neoadjuvant Pembrolizumab/Chemotherapy Approved by European Commission for Locally Advanced, Early-Stage TNBCMay 29th 2022
European patients with locally advanced or early-stage triple-negative breast cancer at high risk of recurrence can now receive treatment with neoadjuvant pembrolizumab and chemotherapy, as well as pembrolizumab monotherapy post surgery following its approval by the European Commission.
Switch Maintenance Endocrine Therapy With Bevacizumab Shows Promise in ER+ HER2– Advanced Breast CancerMay 20th 2022
Patients with estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer may receive alternative treatment with switch maintenance endocrine therapy and bevacizumab and experience notable efficacy and improved safety vs continued weekly paclitaxel and bevacizumab.
Black Women With Early HR+ Breast Cancer Have Shorter RFS and OS Vs White WomenMay 19th 2022
Findings from a post-hoc analysis identified disparities in Black patients with early hormone receptor–positive breast cancer that could not be explained by early discontinuation of endocrine therapy, clinicopathologic characteristics, insurance coverage, or neighborhood deprivation index.
Earlier MRI Screenings Could Significantly Cut Breast Cancer Mortality for Certain Pathogenic VariantsMay 19th 2022
Breast cancer mortality could be reduced by half for patients with ATM, CHEK2, and PALB2 pathogenic variants who undergo annual MRI screenings between the ages of 30 to 35 years and annual MRI screenings and mammography for those 40 or older.
Ibrutinib Plus Rituximab Yields Superior Survival Vs FCR in CLL, Regardless of IGHV StatusMay 18th 2022
Patients with untreated, IGHV-mutated and -unmutated chronic lymphocytic leukemia experienced better overall survival and progression-free survival with ibrutinib and rituximab compared with fludarabine, cyclophosphamide, and rituximab.
Final PFS Analysis Shows Promise of Sugemalimab in Stage III Non–Small Cell Lung CancerMay 18th 2022
Final end point analysis of the GEMSTONE-301 trial confirmed that patients with stage III non–small cell lung cancer experienced significant clinical benefit and promising efficacy following consolidation therapy with sugemalimab monotherapy.
Durvalumab Plus Olaparib Is Well Tolerated But Misses Trial End Point of PFS in Advanced Endometrial CancerMay 17th 2022
Findings from the phase 2 DOMEC trial showed that although durvalumab plus olaparib was well tolerated, it missed the study’s primary end point of progression-free survival in patients with metastatic or recurrent endometrial cancer.
First-Line Nivolumab/Ipilimumab Fails to Improve OS Vs Chemotherapy in PD-L1–Low Unresectable or Metastatic Urothelial CarcinomaMay 16th 2022
Patients with untreated unresectable or metastatic urothelial carcinoma and PD-L1 expression of 1% or more who received treatment with nivolumab and ipilimumab in the first-line setting did not experience an improved overall survival vs those getting standard-of-care chemotherapy, according to a final analysis of a phase 3 trial.